原发性肾病综合征患儿CD4+CD2 5+调节性T细胞的变化及临床意义

目的 探讨原发性肾病综合征(PNS)患儿外周血淋巴细胞亚群及CD4+CD25+调节性T细胞的变化及其临床意义.方法 采用流式细胞术检测23例PNS(肾病组)患儿外周血T淋巴细胞亚群,同时检测17例健康儿童作为对照组.结果 PNS患儿外周血中CD4+CD25+淋巴细胞较正常对照组明显升高(P＜0.05).结论 体内异常的CD4+CD25+调节性T细胞水平参与了PNS的发病过程.PNS患儿存在细胞免疫功能紊乱,纠正或调节细胞免疫功能可应用于PNS的临床治疗.     

狼疮性肾炎患儿外周血CD4+CD25+调节性T细胞的变化

目的 探讨狼疮性肾炎(LN)患儿外周血CD4+CD25+调节性T细胞(Tregs)的变化及意义.方法 采用流式细胞术检测30例LN患JL(LN组)和30例健康儿童(对照组)外周血CD4+CD25+调节性T细胞百分比,并分析其与24-h尿微量白蛋白(UMA)及狼疮活动指数(SLE-DAI)的关系.结果 LN患儿外周血中CD4+CD25+Tregs明显低于对照组(P<0.01);CD4+CD25+Tregs 与24-h UMA呈显著负相关,与SLE-DAI呈等级负相关.结论 LN患儿外周血CD4+CD25+Tregs百分比异常降低可能参与LN的起病与发展.CD4+CD25+Tregs百分比与24-h UMA呈显著负相关,与SLE-DAI呈等级负相关,提示可以作为监测LN患儿病情及预后的指标.     

CD4~+CD25~+调节性T细胞在晚期肺癌中的表达及临床意义

目的探讨CD4+CD25+调节性T细胞(Treg细胞)在晚期肺癌中的表达及其临床意义。方法应用流式细胞术分析30例晚期肺癌患者外周血CD4+CD25+Treg细胞表达水平,与10例健康人比较。结果晚期肺癌患者外周血CD4+CD25+Treg细胞数量增加(17.9±6.1)%,表达高于正常人(6.81±0.4)%(P<0.001)。肺癌患者外周血中Treg细胞数量与患者的病理类型无关(P>0.05),但与临床分期和组织学分化程度有关(P<0.01)。结论Treg细胞在肺癌患者中比率明显升高,并与临床进展有关。     

香菇多糖对原发性肝癌TACE前后外周血CD4+CD25+调节性T细胞的影响

目的 观察香菇多糖在原发性肝癌(TACE)前后对外周血CD4+CD25+调节性T细胞的变化,探讨香菇多糖对原发性肝癌患者的免疫调节机制.方法 原发性肝癌46例,随机分为治疗组24例,对照组22例,治疗组在TACE术后第1天给予香菇多糖1 mg,3次/周,两组化疗方案相同,在TACE前及TACE后4周分别抽外周血,应用流式细胞术检测CD4+CD25+调节性T细胞的变化.结果 外周血CD4+CD25+Treg细胞占CD4+T细胞的百分率:治疗组在TACE前为(10.59±4.34)%、TACE后4周(6.72±2.60)%;对照组在TACE术前为(10.21±4.42)%、TACE后4周为(8.56±3.12)%.在TACE前两组间差异无统计学意义(P>0.05);TACE后4周时治疗组较对照组低,两组间差异有统计学意义(P<0.05).结论 香菇多糖可提高恶性肿瘤患者的免疫功能,在TACE后立即给药效果更佳.     

CD4+CD25+T淋巴细胞在支气管哮喘患者外周血的表达及意义

目的 探讨外周血CD4+CD25+T淋巴细胞与支气管哮喘的关系.方法 用流式细胞术分别检测支气管哮喘患者34例(A组)和健康人25例(B组)外周血CD4+CD25+T淋巴细胞的百分率,采用ELISA法检测外周血血清白细胞介素10(IL-10)水平,用化学发光法检测外周血IgE水平,并分析CD4+CD25+T淋巴细胞与外周血IgE及IL-10水平的相关性.结果 A组外周血CD4+CD25+T淋巴细胞百分率显著低于B组[(5.90±1.10)%vs.(7.13±1.48)%](P<0.05),且与血IL-10呈正相关,与IgE呈负相关(P<0.05).结论 CD4+CD25+T淋巴细胞在支气管哮喘患者中高表达,与IL-10及IgE有一定的相关性,是参与支气管哮喘的发生、发展的重要T淋巴细胞.     

过敏性紫癜患儿外周血CD4~+CD25~+CD127~-调节性T细胞表达及意义

目的探讨过敏性紫癜(schonlein-henoch purpura,HSP)患儿治疗前后外周血CD4+CD25+CD127-调节性T细胞的表达及其临床意义。方法采用免疫荧光流式细胞技术检测56例HSP患儿治疗前后及20例健康儿童外周血CD4+CD25+CD127-调节性T细胞的表达值。结果 HSP患儿治疗前CD4+CD25+CD127-调节性T细胞的表达值明显低于治疗后组和正常对照组(P<0.01),HSP治疗后组CD4+CD25+CD127-调节性T细胞表达值与正常对照组相比差异无统计学意义(P>0.05)。结论 HSP治疗前患儿外周血CD4+CD25+CD127-调节性T细胞的表达值较正常对照组明显降低,而在治疗有效后升高,说明调节性T细胞可能参与了HSP的发病和病情的发展。而CD4+CD25+CD127-Treg细胞水平的检测可作为对HSP患儿预后判断的一个有效指标。     

哮喘患者外周血单个核细胞CD4~+CD25~+调节性T细胞及IL-4分泌水平的检测

目的:探讨CD4+CD25+调节性T细胞在哮喘发病机制中的作用,为哮喘的临床治疗提供新的思路和方法。方法:分离哮喘患者和正常人外周血单个核细胞(PBMC),用流式细胞仪分析CD4+CD25+调节性T细胞在外周血单个核细胞中的比例;酶联免疫吸附法(ELASA)检测外周血PBMC培养上清IL-4的分泌状况。结果:哮喘组外周血CD4+CD25+调节性T细胞的百分率为(3.2±1.5)%,健康对照组为(6.5±2.5)%,哮喘组明显低于对照组(P<0.05);哮喘组外周血PBMC培养上清IL-4分泌水平为(57.3±13.5)ng/L,健康对照组为(28.6±7.2)ng/L,哮喘组明显高于对照组(P<0.05)。结论:CD4+CD25+调节性T细胞可能参与了哮喘的发生与发展。     

CD4+CD25+调节性T细胞在再生障碍性贫血中的表达及意义

目的:探讨再生障碍性贫血(再障)患者治疗前、后外周血T淋巴细胞亚群、CD4+CD25+T细胞的变化及其临床意义.方法:采用流式细胞术检测23例再障患者治疗前、后外周血T淋巴细胞亚群、CD4+CD25+T细胞的比例,并与健康对照组进行比较.结果:(1)再障患者治疗前CD4+,CD4+/CD8+,CD4+CD25+明显低于健康对照组(P＜0.01),CD8+细胞则明显升高(P＜0.05);重型再障组与慢性再障组比较CD4+CD25+降低,但差异不显著(P＞0.05),CD3+,CD4+,CD4+/CD8+,CD4+CD25+无统计学意义.(2)再障患者治疗后与治疗前相比,CD4+,CD4+/CD8+,CD4+CD25+明显升高(P＜0.01).(3)再障患者治疗有效者与无效者比较CD4+,CD4+/CDs+,CD4+CD25+明显升高(P＜0.01).结论:再障患者存在T淋巴细胞亚群的失调及CD4+CD25+T淋巴细胞的异常表达,且检测外周血T淋巴细胞亚群、CD4+CD25+T细胞有助于了解再障患者的免疫状态、疗效评价及预后判断.     

变应性鼻炎患者外周血CD+4CD+25Treg细胞检测及临床意义

目的 了解变应性鼻炎患者外周血CD+4 CD+25 Treg细胞含量并探讨其临床意义.方法 采用流式细胞仪分别检测变应性鼻炎15例外周血淋巴细胞中CD+4 T细胞占T细胞比例以及CD+4 CD+25 Treg细胞占CD+4 T细胞的比例,并与15例健康对照者进行比较.结果 变应性鼻炎患者外周血CD+4 T细胞占T细胞比例与对照组比较差异无统计学意义(P＞0.05);变应性鼻炎患者外周血中CD+4 CD+25 Treg细胞、Foxp3+ CD+4 CD+25 T细胞占CD+4 T细胞的比例与对照组比较差异有统计学意义(P＜0.05),2组比较差异无统计学意义(P＞0.05).结论 变应性鼻炎患者CD+4 CD+25 Treg细胞在外周血中比例明显减少,这可能在变应性鼻炎的发病机制中起重要作用.     

猪囊尾蚴病患者CD4~+ CD25~+调节性T细胞水平的变化

目的检测猪囊尾蚴病患者外周血中CD4+CD25+调节性T淋巴细胞及其FOXP3的表达情况,探讨CD4+CD25+调节性T淋巴细胞在猪囊尾蚴感染中的免疫调控作用及意义。方法采用流式细胞仪检测11例猪囊尾蚴病患者外周血中CD4+CD25+T淋巴细胞的含量,同时观察CD4+CD25+T细胞中表达FOXP3群体的百分含量。结果囊尾蚴病患者外周血中CD4+CD25+T淋巴细胞的百分含量为6.11%,较正常人(3.94%)明显升高(P<0.05);患者外周血中CD4+CD25+T细胞表达FOXP3的细胞百分含量为15.67%,与正常对照组(11.09%)有显著性差异(P<0.05)。结论猪囊尾蚴病患者外周血中CD4+CD25+T淋巴细胞的百分含量显著升高,表明CD4+CD25+调节性T细胞可能参与猪囊尾蚴感染的免疫抑制。     

CD4+CD25+调节性T细胞与儿科疾病

古希腊特尔斐阿波罗神庙上镌刻着一句铭言:Gnothi Seauton(英文为know thyself)即"认识自己"."认识自己"已成为免疫学家广为认可的定律:机体免疫系统首先必须识别自身的抗原,产生无反应性,再针对外来抗原产生免疫应答,即"识别自身,排斥异己".     

孕妇外周血CD4+CD25+调节性T细胞对子痫前期的预测

目的:探讨孕妇外周血CD4+ CD225+调节性T细胞(CD4 CD25+ Tregs)对子痫前期的预测价值.方法:选取190例于我院产前常规孕期体检及分娩的孕产妇作为研究对象,按孕产妇是否发生子痫前期分为子痫前期组及正常对照组,采用流式细胞仪测定各孕妇20～24周外周血单个核细胞(PBMC)中CD4T细胞及CD4 CD25+ Tregs的比率,并随访至分娩.采用磁珠分选技术分选随访期间确诊子痫前期的患者外周血PBMC中CD4 CD25+ Tregs和CD4CD25T细胞,酶联免疫仪检测CD4 CD25+ Tregs对CD4CD25T细胞增殖的抑制作用,并与正常孕妇组对比.结果:①随访情况.190例孕产妇妊娠期内有15例发展为子痫前期,其余175例为正常分娩,2组在剖宫产率、胎儿心率异常率、新生儿1 min及5 min的Apgar评分有显著性差异(P＜0.05).②CD4 CD25+ Tregs的数量.子痫前期组和正常对照组外周血PBMC中CD4T细胞比率分别为34.21％±6.92％和35.72％±7.45％,2组比较无显著性差异(P＞0.05).子痫前期组外周血PBMC中CD4 CD25+ Tregs占CD4T细胞的比率为6.71％±2.21％,明显低于正常对照组的12.01％±2.98％(P＜0.05).③CD4 CD25+ Tregs的抑制功能.子痫前期组CD4 CD25+ Tregs对CD4 CD25-T细胞增殖的抑制百分率为57.56％±9.47％,正常孕妇组为78.27％±12.43％,2组比较有显著性差异(P＜0.05).④CD4 CD25+ Tregs的预测性.以CD4+ CD25+ Trges数量变化预测子痫前期的ROC曲线下面积为0.913,Tregs的最佳截断点为6.605％,预测子痫前期的敏感度86.7％、特异度82.85％.结论:孕妇妊娠中期外周血CD4 CD25+ Tregs数量减少和(或)抑制功能下降与子痫前期的发生相关,可作为子痫前期的预测性指标.     

The generation and antigen-specificity of CD4+CD25+ regulatory T cells

CD4+CD25+ regulatory T cells are essential components of the immune system. They help to maintain immune tolerance by exerting suppressive effects on cells of the adaptive and innate immune system. In the last few years there has been an abundance of papers addressing the suppressive effects of CD4+CD25+ regulatory T cells and their putative role in various experimental disease models and human diseases. Despite the enormous amounts of data on these cells a number of controversial issues still exists. CD4+CD25+ regulatory T cells were originally described as thymus-derived anergic/suppressive T cells. Recent papers however indicate that these cells might also be generated in the periphery. Due to the thymic development of CD4+CD25+ regulatory T cells it was thought that these cells were specific for self-antigens. Indeed it was shown that CD4+CD25+ regulatory T cells could be positively selected upon high affinity interaction with self-antigens. However, evidence is accumulating that these cells might also interact with non-self antigens. Finally, in the literature there is conflicting evidence regarding the role of soluble factors versus cell-contact in the mechanism of suppression. The aim of this review is to summarize the evidence supporting these opposing viewpoints and to combine them into a general model for the origin, function and antigen-specificity of CD4+CD25+ regulatory T cells.     

CD4+CD25+ regulatory T cells in health and disease

1. Over the past 5 years, tremendous progress has been made in understanding the suppressive mechanisms of T regulatory (Treg) cells. The Treg cells, a subpopulation of T cells, have been shown to play an important role in maintaining peripheral tolerance and the prevention of autoimmunity. 2. Various populations of Treg cells have been described, including thymically derived CD4(+)CD25(+) Treg cells. These naturally occurring Treg cells are present in the periphery and are capable of suppressing proliferation and effector T cell responses both in vitro and in vivo. 3. In addition, a second subset of Treg cells, type 1 T regulatoary (Tr1) and Th3 cells, exert their suppressive capacity via cytokines such as interleukin-10 and transforming growth factor-beta and are contact independent. 4. The present review summarizes the characteristics and molecular basis of CD4(+)CD25(+) Treg cells, as well as their therapeutic potential in modulating inflammatory diseases, such as inflammatory bowel disease and rheumatoid arthritis.     

Targeting CD4+CD25+FoxP3+ regulatory T-cells for the augmentation of cancer immunotherapy

CD4+CD25+FoxP3+ T-regulatory (Treg) cells are vital to the maintenance of peripheral self tolerance and are implicated in tolerance to foreign antigens. Increasing evidence shows that Treg cells may also play an important role in immune evasion mechanisms employed by cancer. Treg cells are actively recruited and induced by tumors to block innate and adaptive immune priming, effector function and memory response, which can inhibit the efficacy of therapeutic cancer vaccines. As such, modulation of Treg cell function in cancer has been studied using various approaches, with encouraging preclinical and clinical findings. However, controlled and effective modulation of Treg cell function for cancer therapeutics will be contingent on a better understanding of the molecular basis of Treg cell interaction with tumor cells and ensuing immunosuppressive mechanisms.     

Generation of CD2+CD8+ NK Cells from c-kit+ Bone Marrow Cells in Porcine

Natural killer (NK) cells provide one of the initial barriers of cellular host defense against pathogens, in particular intracellular pathogens. Because bone marrow-derived hematopoietic stem cells (HSCs), lymphoid protenitors, can give rise to NK cells, NK ontogeny has been considered to be exclusively lymphoid. Here, we show that porcine c-kit⁺ bone marrow cells (c-kit⁺ BM cells) develop into NK cells in vitro in the presence of various cytokines [interleukin (IL)-2, IL-7, IL-15, IL-21, stem cell factor (SCF), and fms-like tyrosine kinase-3 ligand (FLT3L)]. Adding hydrocortisone (HDC) and stromal cells greatly increases the frequency of c-kit⁺ BM cells that give rise to CD2⁺CD8⁺ NK cells. Also, intracellular levels of perforin, granzyme B, and NKG2D were determined by RT-PCR and western blotting analysis. It was found that of perforin, granzyme B, and NKG2D levels significantly were increased in cytokine-stimulated c-kit⁺ BM cells than those of controls. And, we compared the ability of the cytotoxicity of CD2⁺CD8⁺ NK cells differentiated by cytokines from c-kit⁺ BM cells against K562 target cells for 28 days. Cytokines-induced NK cells as effector cells were incubated with K562 cells as target in a ratio of 100:1 for 4 h once a week. In results, CD2⁺CD8⁺ NK cells induced by cytokines and stromal cells showed a significantly increased cytotoxicity 21 days later. Whereas, our results indicated that c-kit⁺ BM cells not pretreated with cytokines have lower levels of cytotoxicity. Taken together, this study suggests that cytokines-induced NK cells from porcine c-kit⁺ BM cells may be used as adoptive transfer therapy if the known obstacles to xenografting (e.g. immune and non-immune problems) were overcome in the future.     

雷帕霉素诱导大鼠体内CD4+CD25+FoxP3+调节性T细胞的增殖

目的 探讨雷帕霉素(RPM)对大鼠CD4+CD25+FoxP3调节性T细胞的影响.方法 大鼠20只随机均分为两组:实验组RPM 2 mg·kg-1·d-1灌胃2周;对照组用生理盐水替代.无菌件下下腔静脉采血,并分离脾脏及胸腺,制备单个核细胞悬液.采用流式细胞术检测大鼠外周血、脾脏及胸腺内CD4+CD25+T细胞的占单个核细胞的比例,实时定量-PCR检测脾脏细胞FoxP3 mRNA表达,ELISA检测外周血血清转化生长因子β(TGF-13)和白细胞介素10(IL-10)含量.结果 实验组外周血、脾脏和胸腺中CD4+CD25+T细胞的比例明显高于对照组(P＜0.05).实验组大鼠脾脏细胞FoxP3 mRNA表达为对照组的4.1倍.实验组TGF-β和IL-10显著高于对照组(P＜0.05).结论 RPM能诱导大鼠体内CD4+CD25+FoxP3+调节性T细胞增殖,且增加体内免疫抑制性细胞因子TGF-β和IL-10的分泌.     

Resveratrol induces the suppression of tumor-derived CD4+CD25+ regulatory T cells

CD4+CD25+ regulatory T cells (Treg cells) are negative regulator of the immune system and main obstacles to cancer immunotherapy in tumor-bearing hosts. Resveratrol is a natural product found in grapes with both immunomodulatory and anticancer effects, which can be controlled by Treg cells. Therefore, to determine whether resveratrol performs these actions via Treg cells, we investigated changes in Treg cell population and immunomodulatory cytokines in EG7 tumor-bearing C57BL/6 mice. In the present study, CD4+CD25+ cell population among CD4+ cells was inhibited ex vivo by resveratrol treatment in a dose-dependent manner. FoxP3+ expressing cells among CD4+CD25+ population were significantly reduced after resveratrol treatment ex vivo in intracellular FACS analysis. Single intraperitoneal administration of 4 mg/kg resveratrol suppressed the CD4+CD25+ cell population among CD4+ cells and downregulated secretion of TGF-beta, an immunosuppressive cytokine, measured from the spleens of tumor-bearing mice. Furthermore, resveratrol enhanced IFN-gamma expression in CD8+ T cells both ex vivo and in vivo,leading to immune stimulation. Taken together, these results suggest that resveratrol has a suppressive role on CD4+CD25+ cell population and makes peritumoral microenvironment unfavorable to tumor in tumor-bearing mice. Thus, resveratrol can be considered as possible adjuvant material for vaccination-based cancer therapy.     

造血移植物中CD3~+CD8~(low)和CD3~+CD4~-CD8~(low)细胞亚群的检测及分析

目的检测造血移植物(正常人骨髓、脐血及动员后外周血)中CD3+CD8low和CD3+CD4-CD8low细胞亚群,探讨其促进造血干/祖细胞植入异基因骨髓的功能,以期拓宽脐血移植的应用范围。方法直接三色免疫荧光标记流式细胞术检测。结果CD3+CD8low和CD3+CD4-CD8low细胞亚群占CD3+细胞亚群的比例在骨髓中最高,为(8.61±1.40)%,动员后外周血次之,为(5.11±0.76)%,脐血最低,为(3.31±0.88)%(P<0.01);"初始"T(CD45RA+CD45RO-)细胞亚群占CD8low细胞亚群的比例为脐血(94.26±2.46),骨髓(58.68±7.57),动员后外周血(73.21±3.60),"初始"T占CD8high细胞亚群的比例为脐血(82.63±3.16),骨髓(38.69±3.24),动员后外周血(51.58±4.23),各移植物中"初始"T细胞亚群占CD8low细胞亚群的比例均高于其占CD8high细胞亚群的比例(P<0.01),CD8low细胞亚群中"初始"T与"记忆"T(CD45RA-CD45RO+)细胞亚群的比例均高于二者在CD8high细胞亚群的比例。结论脐血CD8low和CD8lowCD4-细胞占CD3+细胞的比例明显低于骨髓,可能是脐血移植植入延迟的原因之一;"初始T与"记忆"T细胞亚群的比例增高,可能与CD3+CD8low细胞亚群维持和诱导免疫耐受,不引起移植物抗宿主病有关。